CELLECT
Tissue collection, identification, chain-of-custody, and transportation procedures.
Verified evidence window · 2013–2014
American
CryoStem
A public biotechnology company, a detailed international medical-tourism proposal, and Benny Doro's firsthand account of advisory, marketing, financing-support, and government-introduction work—preserved without turning recollection into filed fact.
- Public symbol
- CRYO
- Record focus
- Cellular platform · Antigua development proposal
- Executive
- Benny Doro
- Research status
- Published living archive · role documentation requested
Executive Snapshot
A documented company. Verified share ownership. A role still being completed by private evidence.
- Issuer
- American CryoStem Corporation
- Corporate formation
- Nevada · March 13, 2009
- Operating transition
- ACS Global asset acquisition · April 20, 2011
- Verified evidence window
- July 15, 2013 ownership artifact · 2014 Antigua proposal
- Antigua proposal
- New local entity · laboratory · treatment facility · bio-tourism
- Verified ownership
- 200,000 common shares · certificate no. 03268 · July 15, 2013
- Benny evidence boundary
- Ownership documented by original certificate; advisory and international-development responsibilities recalled firsthand; formal role documents pending
Oral History · Benny Doro
The Antigua opportunity, told by the person who proposed it.
This recording is preserved as first-person testimony. It supplies relationship, motivation, meeting, and executive-role context that the public filings do not contain. It is not substituted for documentary proof.
Open indexed narration guide
- Anthony Dudzinski, Charlie McLaughlin, John Arnone, and the relationship context.
- The adipose-tissue collection, storage, and international-treatment concept.
- Benny's recalled marketing, social-media, team-building, and financing-support role.
- The Antigua idea, trip, and government meeting account.
- The project fades; Benny describes the investment position and growing distance from operations.
- Retrospective assessment and later regulatory context.
The Public Company · SEC record
A cellular-technology business entered the issuer in 2011.
The issuer was incorporated in Nevada in 2009. On April 20, 2011, a wholly owned acquisition subsidiary acquired substantially all assets and liabilities of ACS Global in exchange for 21,000,000 common shares.
At closing, ACS Global became the majority shareholder. John Arnone became Chief Executive Officer and President; Anthony F. Dudzinski became Chief Operating Officer, Treasurer, and Secretary; both joined the board.
A contemporaneous private placement sold 1,860,000 common shares at $0.50 for $930,000 in gross proceeds.
These are filed corporate events. Benny Doro's ownership is independently documented by an original July 15, 2013 certificate. His advisory responsibilities and the later Antigua work remain separately classified by evidence type.
The Platform · contemporary company material
From tissue collection to processing, storage, and licensing.
The supplied 2014 materials describe a modular adipose-tissue platform. Product descriptions remain company statements unless independently established.
ATGRAFT
Processing and cryogenic storage of adipose tissue for later grafting procedures.
ATCELL
Adipose-derived cellular products described in company technical and clinical material.
ACSelerate
Media for transport, expansion, differentiation, and storage applications.
Turnkey cGMP platform
Laboratory design, validated SOPs, training, quality systems, and international licensing.
Proposal, not outcome
Market size, physician economics, efficacy, and expansion figures are preserved as proposal-era claims.
Leadership · independently corroborated
The operating and laboratory responsibilities were documented.
The SEC record supplies the formal titles. The Antigua deck supplies the contemporary project contact.
John S. Arnone
SEC filings identify Arnone as Chairman and CEO and describe his association with American CryoStem beginning in 2008.
Anthony F. Dudzinski
Filings assign Dudzinski responsibility for operational and laboratory infrastructure and regulatory compliance. He also signed filings as Treasurer and Secretary.
Anthony F. Dudzinski
The 2014 Antigua investor presentation lists Dudzinski's contact information, independently connecting him to the proposal package.
Benny Doro · evidence separated by type
The executive role is preserved without being overstated.
Marketing and social-media advisor
Benny recalls being brought in to advise on online presence and marketing and assembling a team to support that work.
Financing support
He recalls that he and Charlie McLaughlin assisted with financing. No amount or formal financing title is assigned without transaction records.
Antigua origin and introductions
He recalls proposing Antigua, traveling with Dudzinski, and arranging meetings with government and medical participants.
200,000-share ownership
Original American CryoStem certificate no. 03268 names Benny Doro as owner of 200,000 common shares and is dated July 15, 2013.
Consultant shares were issued in the same quarter
The fiscal 2013 Form 10-K reports 660,000 consultant shares issued for services after June 30 and before September 30, 2013. The certificate falls within that period, but the filing does not name Benny and the exact linkage remains unproven.
No officer or director title assigned
The current evidence does not support describing Benny as an American CryoStem officer or director.
Antigua Bio-Tourism · 2014
A two-phase international development proposal.
The recovered documents turn the Antigua chapter from recollection into a documented corporate proposal. They do not establish completion.
- 01Organize local companyLocal stakeholders · government · medical community · investors
- 02Set budget and financingRequired by the proposal · no completed financing instrument recovered
- 03Build and validate laboratoryCommercial adipose-tissue processing and storage platform
- 04Affiliate treatment centerUse existing facilities during Phase 1
- 05Construct Phase 2 facilityProposed world-class bio-tourism and integrative-treatment center
Meeting account
Benny recalls arranging a meeting with Prime Minister Gaston Browne, a senior government official, a leading Antiguan physician, Anthony Dudzinski, and James Richards. The proposal corroborates planned government collaboration; participant identities, meeting date, and photographs remain pending.
Evidence Library · originals preserved
The ownership artifact and proposal can be examined in their original form.
Each supplied artifact is preserved unchanged. Company presentations are evidence of what was proposed and represented at the time—not independent proof that every claim or projection was achieved.
Ownership and SEC chronology 3 primary sources
- Original Stock Certificate · July 15, 2013Direct evidence of 200,000 certificated common shares registered to Benny Doro.
- SEC Form 10-Q · quarter ended June 30, 2013Capitalization immediately before the certificate date; no consultant-share issuance reported through June 30.
- SEC Form 10-K · fiscal 2013Reports 660,000 consultant shares issued for services during the fiscal year; exact recipient linkage remains pending.
Antigua development package 3 documents
- Antigua Investor Presentation · 2014Local entity, stakeholder model, phased facilities, financing sequence, products, Dudzinski contact.
- Commercialization Strategy — AntiguaMedical-tourism directory, search/social marketing, partnerships, events, and regional positioning.
- Adipose-Derived Stem Cells: The Next Frontier of Medical TourismMedical-tourism thesis, patient questions, clinical standards, and company claims.
Laboratory and product platform 3 documents
- Clinical Adipose Tissue Processing Platform · Laboratory OverviewTurnkey laboratory, SOPs, products, and international licensing.
- ATGRAFT Overview · 2014Collection, processing, storage workflow, physician presentation, and proposal-era economics.
- ACSelerate White PaperCompany technical material on cellular expansion and culture.
Technical literature 2 documents
- ATCELL PaperTechnical material describing the company's adipose-derived cell product.
- Today's Pathways to Tomorrow's TherapiesScientific article with technical discussion and cited literature.
Public and regulatory record 3 primary sources
- SEC Form 10-K · fiscal 2015Corporate history, leadership, operations, capitalization, and option-plan disclosures.
- FDA Warning Letter · January 3, 2018Later regulatory history, separated from Benny's chapter.
- SEC Registration Revocation Order · April 2024Later public-company endpoint.
Photographic evidence architecture
Antigua meeting and travel gallery reserved.
The record is ready to receive the original Antigua photographs with filenames, metadata, participant identifications, and source notes. No substitute or recreated images will be used.
Later corporate history · separated from 2013–2014
The regulatory record came years later.
- FDA inspectionFDA inspected the Monmouth Junction facility and documented observations concerning ATCELL and manufacturing controls.
- FDA warning letterFDA addressed ATCELL's regulatory status and significant manufacturing-practice deviations.
- Last periodic report cited by SECThe later SEC order states the company filed no periodic reports after this period.
- Registration revokedSEC revoked registration of each registered class of CRYO securities.
Editorial boundaryLater company conductNo later FDA, reporting, governance, or regulatory event is attributed to Benny Doro without evidence of involvement.2017–2024
Open Evidence
The record states exactly what is still missing.
- Certificate linkage: stock ledger, board authorization, or consulting agreement connecting certificate no. 03268 to a specific disclosed issuance.
- Formal role: advisory agreement, board resolution, correspondence, or other record defining Benny's title, services, compensation, and period of involvement.
- Antigua photographs: originals with metadata and participant identifications.
- Meeting record: exact date, agenda, official titles, physician identity, and government correspondence.
- Financing trail: wires, agreements, brokerage statements, or private-placement schedules.
- Outcome: evidence of any formed local company, approvals, committed financing, construction, or operations.
Archival rule: absence of a public filing does not disprove a private role. It means the private evidence must be recovered and labeled on its own terms.